Immunome Announces IND Clearance for IM-1340, a Potential First-in-Class Antibody-Drug Conjugate for the Treatment of Solid Tumors
Key Highlights
- ➤FDA cleared IND for IM-1340, Immunome’s (IMNM) potential first-in-class solid-tumor ADC
- ➤Phase 1 first-in-human study expected to begin in fourth quarter of 2026
- ➤IM-1340 uses proprietary HC74 TOP1 inhibitor payload and targets solid-tumor transport receptor
- ➤Preclinical studies showed anti-tumor activity, including single-dose tumor regressions in multiple models
Expert Statements
Clay Siegall, President and Chief Executive Officer of Immunome
“IND clearance for IM-1340 marks another milestone in the advancement of Immunome's ADC platform and demonstrates our ability to rapidly progress novel HC74-based programs into the clinic”
Clay Siegall, President and Chief Executive Officer of Immunome
“We believe IM-1340 has the potential to treat multiple solid tumor types by combining a differentiated target with the favorable properties of our proprietary HC74 payload”
Clay Siegall, President and Chief Executive Officer of Immunome
“We look forward to initiating clinical evaluation of IM-1340 and continuing to expand our ADC pipeline.”
Immunome Announces IND Clearance for IM-1340, a Potential First-in-Class Antibody-Drug Conjugate for the Treatment of Solid Tumors
* IM-1340 incorporates Immunome's proprietary HC74 topoisomerase I inhibitor payload and targets a transport receptor expressed across solid tumors, including neuroendocrine tumors, lung cancer, and colorectal cancer * Company expects to initiate Phase 1 first-in-human study in patients with advanced solid tumors in the fourth quarter of 2026 * IM-1340 is Immunome’s fifth program in clinical development Immunome, Inc. (Nasdaq: IMNM), a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for IM-1340, a potential first-in-class antibody-drug conjugate (ADC) for the treatment of advanced solid tumors.
Get started
Create a free account to read the full story.